Mark Matta, DO
Psychiatry · New Castle, PANPI 1245424084
Payments from drug & device makers
Across 1,967 payments — averaging $430.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$211K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207K
- Alkermes, Inc.$108K
- Otsuka America Pharmaceutical, Inc.$99K
- Vanda Pharmaceuticals Inc.$99K
- AbbVie$51K
- plus $73K from 33 others
What the payments were for
- Consulting fees$29,6083%
- Speaking & faculty fees$633,57375%
- Travel & lodging$144,13917%
- Food & beverage$39,3205%
- Education$7240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$847,364 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 19 | $167,152 |
| LybalviOlanzapine/Samidorphan Malate | 56 | $86,342 |
| CaplytaLumateperone Tosylate | 43 | $67,837 |
| NuplazidPimavanserin Tartrate | 12 | $61,375 |
| TrintellixVortioxetine Hydrobromide | 132 | $59,621 |
| VraylarCariprazine Hcl | 40 | $55,632 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $44,181 |
| RexultiBrexpiprazole | 31 | $37,474 |
| QuviviqDaridorexant Hcl | 39 | $19,636 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $17,315 |
| Adzenys Xr-OdtAmphetamine | 22 | $10,937 |
| BelsomraSuvorexant | 21 | $8,647 |
| Paliperidone ErPaliperidone | 43 | $5,037 |
| AzstarysSerdexmethylphen/Dexmethylphen | 12 | $4,720 |
| Clozapine | 49 | $4,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $210,915 | $167,15219 claims |
| Alkermes, Inc.Lybalvi | $107,534 | $86,34256 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $206,970 | $67,83743 claims |
| Acadia Pharmaceuticals IncNuplazid | $426 | $61,37512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $3,959 | $59,621132 claims |
| AbbVieVraylar | $51,091 | $55,63240 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $321 | $44,18139 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99,304 | $37,47431 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $14,614 | $19,63639 claims |
| Axsome Therapeutics, Inc.Auvelity | $474 | $17,31515 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $36 | $10,93722 claims |
| MerckBelsomra | $125 | $8,64721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in New Castle
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.